Triptans (anti-migraine agents) can normalize CGRP levels, with a concurrent resolution of migraine (Gallai et al., 1995, Sarchielli et al., 2000), and small molecule CGRP antagonists and antibodies are a promising drug class for episodic and chronic migraine treatment (Negro et al., 2012, Goadsby et al., 2017, Dodick et al., 2018). The gene discussed is CALCA; the disease is migraine disorder.